[Lysozyme activity in undiluted and diluted blood of patients treated with cyclosporin A with prednisone or azathioprine with prednisone after kidney transplantation].
It is a general opinion that the renal transplant patients may show the decrease of immunity which manifests by their increased susceptibility to bacterial, viral and fungal infections. One of the important non-specific defensive factors of the organism participating in the protection against infections is lysozyme. It is the purpose of the present paper to estimate the lysozyme activity in the un- and diluted serum in the renal transplant patients and to determine the possible mechanism of the observed deviations. 32 renal transplant patients (24 men and 8 women) aged of 16 up to 50 were investigated, being in the period of 1 until 4 years after transplantation. In the investigation the kind of immunosuppressive treatment used was considered which served the purpose of dividing the total group of patients into two subgroups: one treated with cyclosporine (12 patients) and the other treated with azathioprine (20 patients). The control group consisted of 20 healthy persons, matching by age, sex and living place the group investigated. In both groups investigated and control, were determined: lysozyme activity in the serum of the undiluted and diluted blood, total leukocyte number, the absolute number of peripheral blood neutrophils as well as their adherence to fibres was evaluated. In the renal transplant patients compared with the control group and in the separated subgroups, no statistically significant differences were found concerning leukocyte count, absolute neutrophil count and adherence of those cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Hrycek
A
A
II Katedry i Kliniki Chorób Wewnetrznych, Slaskiej Akademii Medycznej w Katowicach.
Szołtysik
I
I
Grzeszczak
W
W
D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage*; D016572:Cyclosporine / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006082:Graft Enhancement, Immunologic; D006438:Hemodilution; D006801:Humans; D007676:Kidney Failure, Chronic / Q000201:enzymology / Q000276:immunology* / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood*; D011182:Postoperative Care; D011241:Prednisone / Q000008:administration & dosage*
D016572:Cyclosporine; D009113:Muramidase; D001379:Azathioprine; D011241:Prednisone
Aktywność lizozymu w surowicy krwi nierozcieńczonej i rozcieńczonej u chorych po przeszczepieniu nerki leczonych cyklosporyna A z prednizonem lub azatiopryna z prednizonem.